CN104755928B - 奥氮平的抗体及其用途 - Google Patents

奥氮平的抗体及其用途 Download PDF

Info

Publication number
CN104755928B
CN104755928B CN201380054975.6A CN201380054975A CN104755928B CN 104755928 B CN104755928 B CN 104755928B CN 201380054975 A CN201380054975 A CN 201380054975A CN 104755928 B CN104755928 B CN 104755928B
Authority
CN
China
Prior art keywords
seq
antibody
olanzapine
amino acid
complementarity determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380054975.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104755928A (zh
Inventor
E.赫伊霍伦科
B.桑卡兰
T.R.德科里
T.图布斯
L.科特
B.M.雷梅里伊
R.萨特
M.G.多纳胡伊
Y.龚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Ortho Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Ortho Clinical Diagnostics Inc filed Critical Janssen Pharmaceutica NV
Priority to CN201710231010.XA priority Critical patent/CN107253993B/zh
Publication of CN104755928A publication Critical patent/CN104755928A/zh
Application granted granted Critical
Publication of CN104755928B publication Critical patent/CN104755928B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380054975.6A 2012-08-21 2013-08-20 奥氮平的抗体及其用途 Expired - Fee Related CN104755928B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710231010.XA CN107253993B (zh) 2012-08-21 2013-08-20 奥氮平的抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691645P 2012-08-21 2012-08-21
US61/691645 2012-08-21
PCT/US2013/055826 WO2014031662A2 (en) 2012-08-21 2013-08-20 Antibodies to olanzapine and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710231010.XA Division CN107253993B (zh) 2012-08-21 2013-08-20 奥氮平的抗体及其用途

Publications (2)

Publication Number Publication Date
CN104755928A CN104755928A (zh) 2015-07-01
CN104755928B true CN104755928B (zh) 2017-05-10

Family

ID=50148311

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380054975.6A Expired - Fee Related CN104755928B (zh) 2012-08-21 2013-08-20 奥氮平的抗体及其用途
CN201710231010.XA Expired - Fee Related CN107253993B (zh) 2012-08-21 2013-08-20 奥氮平的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710231010.XA Expired - Fee Related CN107253993B (zh) 2012-08-21 2013-08-20 奥氮平的抗体及其用途

Country Status (10)

Country Link
US (3) US9494608B2 (https=)
EP (1) EP2888590B1 (https=)
JP (3) JP6216926B2 (https=)
CN (2) CN104755928B (https=)
AU (3) AU2013305901B2 (https=)
CA (1) CA2882596C (https=)
ES (1) ES2807902T3 (https=)
PL (1) PL2888590T3 (https=)
PT (1) PT2888590T (https=)
WO (1) WO2014031662A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
US9494608B2 (en) * 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
EP3390455A1 (en) * 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CN108431040B (zh) 2015-12-17 2022-07-26 詹森药业有限公司 利培酮的抗体及其用途
US10145855B2 (en) * 2016-05-03 2018-12-04 Synapse Biosciences, LLC Methods and dose packs for monitoring medication adherence
CN119662553B (zh) * 2024-11-26 2025-11-28 江南大学 一种分泌奥氮平类化合物单克隆抗体的杂交瘤细胞株

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
CN102276624A (zh) * 2011-06-17 2011-12-14 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
CN102276592A (zh) * 2011-06-17 2011-12-14 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
CN104854110A (zh) * 2012-08-21 2015-08-19 詹森药业有限公司 奥氮平半抗原

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
CA2101337A1 (en) 1991-02-01 1992-08-02 Stephan D. Glenn Method of producing f(ab')2 fragments of immunoglobulins
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DK0582368T3 (da) 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
CA2192467C (en) 1994-06-10 2009-03-31 Alireza Rezaie Calcium binding recombinant antibody against protein c
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003217936A1 (en) 2002-03-28 2003-10-13 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
AU2003259256A1 (en) 2002-07-29 2004-02-16 Potomac Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
AU2003264915A1 (en) * 2002-08-05 2004-02-25 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
BRPI0413595B8 (pt) 2003-08-18 2021-05-25 H Lundbeck As sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto
ES2335589T3 (es) 2003-09-23 2010-03-30 Fermion Oy Preparacion de quetiapina.
CN101921279A (zh) 2003-10-01 2010-12-22 阿得罗公司 螺环杂环衍生物及其应用方法
DE602004024236D1 (en) 2003-12-12 2009-12-31 Inverness Medical Switzerland Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP2010507648A (ja) * 2006-10-25 2010-03-11 ラモット アット テル−アビブ ユニバーシティー リミテッド グルタミン酸ｎｍｄａ活性を有する新規向精神薬
WO2008082979A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
RU2010116351A (ru) 2007-09-27 2012-05-20 Новартис АГ (CH) Мониторинг лекарственных средств
CN101945894A (zh) * 2007-12-13 2011-01-12 积水医疗株式会社 抗氧氟沙星单克隆抗体和使用其的氧氟沙星免疫测定
EP2320942B1 (en) 2008-07-21 2018-03-14 Probiodrug AG Diagnostic antibody assay
EP2331088A4 (en) 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
EP2349335B1 (en) * 2008-10-24 2013-08-07 ARK Diagnostics, Inc. Levetiracetam immunoassays
EP2347015A4 (en) 2008-10-29 2012-12-19 Janssen Pharmaceutica Nv METHOD FOR THE TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE ERBB4 GEN
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
EP2389169A1 (en) 2009-01-26 2011-11-30 Egalet A/S Controlled release formulations with continuous efficacy
EP2406289B1 (en) 2009-03-10 2017-02-22 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
RU2595843C2 (ru) 2009-10-16 2016-08-27 Омик Аб Способ анализа и устройства с применением магнитных частиц
EP2325322A1 (en) * 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
EP3476218A1 (en) 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) * 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
SG11201501130PA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
ES2652641T3 (es) 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
ES2654413T3 (es) 2012-08-21 2018-02-13 Janssen Pharmaceutica, N.V. Anticuerpos a quetiapina y uso de los mismos
ES2904838T3 (es) 2012-08-21 2022-04-06 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
CA2882562C (en) 2012-08-21 2019-08-27 Eric Hryhorenko Antibodies to aripiprazole and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
US9494608B2 (en) * 2012-08-21 2016-11-15 Janssen Pharmaceutica Nv Antibodies to olanzapine and use thereof
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
ES2788716T3 (es) 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
ES2978909T3 (es) 2012-08-21 2024-09-23 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de aripiprazol y uso de los mismos
EP3462173B1 (en) 2012-08-21 2021-03-31 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
CN104736565B (zh) 2012-08-21 2019-03-12 詹森药业有限公司 利培酮半抗原的抗体及其用途
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
ES2822907T3 (es) 2012-08-21 2021-05-05 Janssen Pharmaceutica Nv Haptenos de quetiapina para su uso en inmunoensayos
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
CN102276624A (zh) * 2011-06-17 2011-12-14 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
CN102276592A (zh) * 2011-06-17 2011-12-14 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
CN104854110A (zh) * 2012-08-21 2015-08-19 詹森药业有限公司 奥氮平半抗原

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The influence of olanzapine on immune cells in patients with schizophrenia;Mustafa Bilici et al;《Progress in Neuro-Psychopharmacology and Biological Psychiatry》;20030331;第27卷(第3期);483-485 *
抗精神病药对代谢的影响比较;汪卫华等;《临床精神医学杂志》;20090228;第19卷(第1期);55-57 *

Also Published As

Publication number Publication date
AU2018200541B2 (en) 2019-09-26
EP2888590A4 (en) 2016-04-13
US20190315885A1 (en) 2019-10-17
US20170037152A1 (en) 2017-02-09
PL2888590T3 (pl) 2020-11-30
HK1212033A1 (en) 2016-06-03
JP6216926B2 (ja) 2017-10-25
AU2018200541A1 (en) 2018-02-15
JP2018039787A (ja) 2018-03-15
JP2019104725A (ja) 2019-06-27
EP2888590B1 (en) 2020-07-08
US10344098B2 (en) 2019-07-09
WO2014031662A3 (en) 2014-04-24
CN107253993B (zh) 2021-10-22
JP2015529202A (ja) 2015-10-05
CA2882596A1 (en) 2014-02-27
AU2013305901A1 (en) 2015-03-05
US11046786B2 (en) 2021-06-29
PT2888590T (pt) 2020-09-11
JP6442008B2 (ja) 2018-12-19
AU2013305901B2 (en) 2017-10-26
EP2888590A2 (en) 2015-07-01
US9494608B2 (en) 2016-11-15
CN107253993A (zh) 2017-10-17
US20140057304A1 (en) 2014-02-27
WO2014031662A2 (en) 2014-02-27
AU2019283820B2 (en) 2022-04-07
CN104755928A (zh) 2015-07-01
ES2807902T3 (es) 2021-02-24
CA2882596C (en) 2019-05-14
AU2019283820A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CN104755928B (zh) 奥氮平的抗体及其用途
CN104755929B (zh) 喹硫平的抗体及其用途
CN104755631B (zh) 阿立哌唑的抗体及其用途
CN104737017B (zh) 利培酮的抗体及其用途
CN104736561B (zh) 帕潘立酮的抗体及其用途
CN108431040B (zh) 利培酮的抗体及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20161223

Address after: Belgium. Beals was Hot Springs Road No. 30.

Applicant after: JANSSEN PHARMACEUTICA N.V.

Address before: New jersey, USA

Applicant before: Ortho-Clinical Diagnostics, Inc.

Applicant before: JANSSEN PHARMACEUTICA N.V.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170510